UPDATE 1-Bristol wins Abilify extension, sees profit boost

* Revised deal protects U.S. Abilify rights until 2015

* Says new terms will boost profit in 2013, 2014

* Says arrangement will help cushion Plavix patent cliff

* Shares rise slightly in premarket trading (Adds analyst comments, bullet points, share price)

By Ransdell Pierson

NEW YORK, April 6 (Reuters) - Bristol-Myers Squibb Co said on Monday it will sell its Abilify schizophrenia drug more than two years longer than expected, helping to shore up profits after the company's $5.6 billion-a-year Plavix blood clot preventer faces generic competition in mid-2012.

Abilify, with global sales last year of $2.15 billion, is Bristol-Myers' second-biggest product and one of its fastest growing. The company had been expected in November 2012 to return U.S. sales rights to the medicine's discoverer, Otsuka Pharmaceutical Co of Japan.

But in a revision to the drugmakers' decade-old licensing deal, Bristol-Myers (BMY.N) said it will now be allowed to sell Abilify in the United States until it loses patent protection in April 2015.

"The extension of the U.S. agreement for Abilify will help Bristol-Myers address an important financial need in 2013," said company spokeswoman Tracy Furey, referring to the first full-year that Plavix faces generics in the United States.